Cargando…
Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646109/ http://dx.doi.org/10.1186/2051-1426-3-S2-P164 |
| _version_ | 1782400916437073920 |
|---|---|
| author | Beer, Tomasz M Vogelzang, Nicholas Bartůňková, Jiřina Miller, Kurt Oh, William Oudard, Stephane Pandha, Hardev Sartor, A Oliver Špíšek, Radek Toole, Timothy O Borgstein, Niels G Gerritsen, Winald R |
| author_facet | Beer, Tomasz M Vogelzang, Nicholas Bartůňková, Jiřina Miller, Kurt Oh, William Oudard, Stephane Pandha, Hardev Sartor, A Oliver Špíšek, Radek Toole, Timothy O Borgstein, Niels G Gerritsen, Winald R |
| author_sort | Beer, Tomasz M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4646109 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46461092015-11-20 Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer Beer, Tomasz M Vogelzang, Nicholas Bartůňková, Jiřina Miller, Kurt Oh, William Oudard, Stephane Pandha, Hardev Sartor, A Oliver Špíšek, Radek Toole, Timothy O Borgstein, Niels G Gerritsen, Winald R J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4646109/ http://dx.doi.org/10.1186/2051-1426-3-S2-P164 Text en Copyright © 2015 Beer et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Beer, Tomasz M Vogelzang, Nicholas Bartůňková, Jiřina Miller, Kurt Oh, William Oudard, Stephane Pandha, Hardev Sartor, A Oliver Špíšek, Radek Toole, Timothy O Borgstein, Niels G Gerritsen, Winald R Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title | Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title_full | Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title_fullStr | Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title_full_unstemmed | Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title_short | Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer |
| title_sort | autologous dendritic cell immunotherapy (dcvac/pca) added to docetaxel chemotherapy in a phase iii trial (viable) in men with advanced (mcrpc) prostate cancer |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646109/ http://dx.doi.org/10.1186/2051-1426-3-S2-P164 |
| work_keys_str_mv | AT beertomaszm autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT vogelzangnicholas autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT bartunkovajirina autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT millerkurt autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT ohwilliam autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT oudardstephane autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT pandhahardev autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT sartoraoliver autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT spisekradek autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT tooletimothyo autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT borgsteinnielsg autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer AT gerritsenwinaldr autologousdendriticcellimmunotherapydcvacpcaaddedtodocetaxelchemotherapyinaphaseiiitrialviableinmenwithadvancedmcrpcprostatecancer |